AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06173141 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: hemodialysis sessions only
Description: hemodialysis sessions only
Study NCT05812300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Freshly manufactured 35 kDa hyaluronan fragment
Description: The study was an open-label clinical trial. A pre- and posttreatment controlled study approach was used, whereby the investigator injected 35 kDa hyaluronan fragment HA35 into the periodontal pocket in a single dose of 100 mg. The distribution of the injection amount was determined by the location of gingival inflammation.
Study NCT04215458 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sample collection (swap or tape strip)
Description: collection of swap or tape strip to determine yeast colonization in skin
Study NCT05834413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy plus TCM 1&ICIs plusTCM2 placebo
Description: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang and Xu Ling. Package of granules is made into two types with functions such as tonifying the stomach and nourishing the blood recipe, benefiting Qi Yin and detoxification and resolving masses recipe. The herbal treatment is adapted to the syndromes.~Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy.
Study NCT05834413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo
Description: Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy.~ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy.
Study NCT05864170 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: β-globin restored autologous hematopoietic stem cells
Description: β-globin-restored autologous hematopoietic stem cells modified with LentiHBBT87Q
Study NCT06281288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy
Description: Cognitive behavioral therapy
Study NCT06281288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Training
Description: Moderate intensity (\~63% maximum heart rate; HRmax) aerobic (\~25 min) and resistance (\~25 min) activities
Study NCT05345054 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: This study will not involve an intervention of any sort. Participants will either take a survey or undergo an interview, and those taking the survey will have clinical data captured.
Study NCT06369623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monetary Incentive Delay Task
Description: The Monetary Incentive Delay functional Magnetic Resonance Imaging task is well-characterized and commonly utilized in research settings to measure neural activation between win and loss conditions, as well as between phases of anticipation and consummation/outcome. A recent meta-analysis indicates that the task has been used in over 80 studies and 5,000 subjects as of Year 2022. The task is also valid and appropriate for use in children and adolescents, as demonstrated by its inclusion in National Institute on Drug Abuse ABCD study. The task is utilized for its short-lived, reversible, and/or benign effects on brain activation (e.g., brief processing of a reward cue).
Study NCT06475820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: GVHD prevention using a combination of post-transplantation cyclophosphamide~Prevention of GVHD:~Cyclophosphamide 80 mg/kg/course on the days +3, +4 Abatacept 10 mg/kg/day on the days +5, +14, +28, +60, +90 Vedolizumab 10 mg/kg/day, max. 300 mg on the days 0, +14, +28, +60 Baricitinib 4 mg/day per os (patient age > 9 years), 2 mg/day (patient age \< 9 years), from day -3 to day +90 (after HSCT), orally, once a day.
Study NCT04870281 — intervention group
Intervention type: DEVICE
Intervention: CRT-DX
Description: Evaluation of overall health, including heart failure and atrial fibrillation improvement, changes in physical fitness, and general quality of life.
Study NCT05579925 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 600 mg + 300 mg, subcutaneous injection
Study NCT04176575 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture involves inserting thin needles into precise points on the body, known as acupuncture points, for therapeutic effect. Acupuncture will be provided by a licensed acupuncturist utilizing Dr. Tan's Balancing Method.
Study NCT05948098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facilitated Tucking Position
Description: a sub-form of method of nesting the baby and the procedure of bringing the body to middle or even close position by holding the upper and lower extremities of the baby in flexion with hands
Study NCT05948098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gentle Human Touch
Description: It is a form of healing touch
Study NCT05464589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation along with pelvic floor muscle srengthening
Description: Pelvic floor muscles strengthening:~Pelvic floor muscles training involves Kegel's exercises. Kegel exercises improve the function and tone of the pelvic floor. Kegel exercises represent the voluntary contraction and relaxation of the levator ani muscle (principally the pubococcygeus and puborectalis portions), which supports the vagina, bladder, and urethra. The slow contractions help with muscle strengthening.~Transcutaneous electrical stimulation of Tibial Nerve:~Transcutaneous Tibial nerve stimulation is a form of treatment technique that involves the use of electrical impulses to address urinary symptoms and target the lower urinary tract.
Study NCT05464589 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscles strengthening
Description: Pelvic floor muscles strengthening:~Pelvic floor muscles training involves Kegel's exercises. Kegel exercises improve the function and tone of the pelvic floor. Kegel exercises represent the voluntary contraction and relaxation of the levator ani muscle (principally the pubococcygeus and puborectalis portions), which supports the vagina, bladder, and urethra. The slow contractions help with muscle strengthening.
Study NCT05542680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cushion
Description: In the intervention group, the special cushion for semi recumbent position was used
Study NCT05368428 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Undergo TENS
Study NCT04738513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertical preparation technique
Description: Teeth in dental esthetic zone will receive Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using vertical preparation technique.
Study NCT04738513 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Preparation technique
Description: Teeth in dental esthetic zone will receive Monolithic Zirconia (5Y-TZP/3Y-TZP) Crowns using conventional preparation technique.
Study NCT05942651 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive brain stimulation protocol (Cortico-cortical paired associative stimulation protocol (ccPAS)) delivered at 4 ms intervals.
Description: The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 4 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT
Study NCT05942651 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-invasive brain stimulation protocol (Cortico-cortical paired associative stimulation protocol (ccPAS)) delivered at 100 ms intervals
Description: The first stimulation will be applied to the IFC and the second to the pre-SMA, with an interstimulation interval set at 100 ms. A total of 180 stimulation pairs will be delivered every 2 s. (5Hz) for a total duration of 15 minutes at an intensity of 120% of rMT
Study NCT05635734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon 5 mg
Description: Azeliragon 5 mg once a day (loading initial dose for 6 days of 10 mg daily). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles.
Study NCT05635734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon 10 mg
Description: Azeliragon 10 mg once a day (loading initial dose for 6 days of 15 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles.
Study NCT05635734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azeliragon 20 mg
Description: Azeliragon 20 mg once a day (loading initial dose for 6 days of 30 mg twice a day). Patients will receive azeliragon for up to 2 years or as long as the patient and study investigator feel that a therapeutic benefit is possible.~Patients will receive involved field radiation therapy and temozolomide consisting of fractionated focal irradiation in daily fractions of 2 Gy given 5 days/week for 6 weeks, for a total of 60 Gy, plus concomitant daily temozolomide (TMZ; 75 mg/m2/day, 7 days/week from the first to the last day of radiotherapy), followed by six cycles of adjuvant TMZ (150-200 mg/m2/day for 5 days during each of six 28-day cycles.
Study NCT06581601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy, exercises
Description: An author's questionnaire will be used for participant selection, asking about the number and course of deliveries. Additionally, participants will log daily activities to calculate the physical activity level coefficient. Weight and height will be measured using a Tanita device to calculate BMI. The posture type and pelvic type will be assessed. Participants will be asked to complete the following questionnaires before and after the intervention: Pelvic Floor Disability Index (PFDI-20), Pelvic Floor Impact Questionnaire Short Form (PFIQ-7 SF), Sexual Satisfaction Scale (SSS-W-R15), Neck Disability Pain Index, Revised Oswestry Low Back Pain Disability Scale, Migraine Disability Assessment (MIDAS), Hospital Anxiety and Depression Scale (HADS), Short Form McGill Pain Questionnaire, CRANIA (Integrated Approach to Cranio Mandibular Neuroscience) questionnaire, IPAQ (International Physical Activity Questionnaire). Modified 1-Hour Pad Test. Execution of the Author's Training Program.
Study NCT04721418 — intervention group
Intervention type: RADIATION
Intervention: 11C-UCB-J
Description: 11C-UCB-J PET scan
Study NCT06058364 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intervention 1 - Triglyceride
Description: Triglyceride (1 softgel each morning with a glass of water)
Study NCT06058364 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Intervention 2 - Placebo
Description: Placebo (1 softgel each morning with a glass of water)
Study NCT06643013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XBD173
Description: 4 weeks treatment
Study NCT06643650 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: CHOLECALCIFEROL ORAL.SOL 25000 IU/2,5ML
Description: Cholecalciferol 25000IU/week for 3 months in both groups. 2nd group continues with 25000IU/month for following 3 months.
Study NCT04494698 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duotherm VibraCool Back Device
Description: Active New multimodal pain device
Study NCT04494698 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TENS 8-channel unit
Description: LG Smart TENS unit
Study NCT06335706 — intervention group
Intervention type: BEHAVIORAL
Intervention: Fit of underpants worn
Description: Tight or loose-fitted underpants
Study NCT05607589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP213388
Description: immunosuppressant
Study NCT05607589 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06446648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICG
Description: Administer an IV ICG injection intraoperatively, using the optimal dosage and timing defined in the second phase of the study. Utilize the newly developed 3D vascular map for visualization of the arteries before and after prostate resection.
Study NCT06189612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical reasoning based physiotherapy + cervical movement control training
Description: An individualized cervical motor control training based on the positive tests of the test battery introduced by Patroncini et al. (2014).
Study NCT06189612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical reasoning based physiotherapy + orofacial movement control training
Description: An individualized orofacial motor control training based on the positive tests of the test battery introduced by von Piekartz et al. (2017).
Study NCT06189612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical reasoning based physiotherapy + standard exercises
Description: A generalized training regimen based on exercises which are taught in physiotherapy training for the neck and scapula region preventing the overlap with exercises of the test batteries.
Study NCT05774275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: In phase Ib: 37.5 mg/m2, 30 mg/m2, d1, q3w; In phase II: recommended phase 2 dose (RP2D), d1, q3w.
Study NCT05774275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 75mg/m2, d1, q3w Doxorubicin hydrochloride will be administered if subject is allergic to Doxil.
Study NCT05774275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: 200 mg, d1, q3w
Study NCT05774275 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: BED=50-60Gy(α/β=10); Radiation dose depends on tumor characteristics and organs at risk.
Study NCT06207968 — intervention group
Intervention type: DEVICE
Intervention: Knee surgery with FH Ortho devices
Description: This clinical investigation is a real-life observatory designed to collect long-term clinical data on patients who have undergone knee joint replacement or knee ligament reconstruction.~In this type of intervention, one or more medical devices distributed by FH ORTHO SAS may be used by surgeons.
Study NCT04733144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: 7,5 mg prednisolone (low dose) 30 mg prednisolone (high dose)
Study NCT04997837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor
Description: Nivolumab/Toripalimab 240mg solution intravenously once daily, Q2W. OR Nivolumab/Toripalimab 360mg solution intravenously once daily, Q3W; OR Pembrolizumab/Tilelizumab/Sintilimab/Carrelizumab, 200mg solution intravenously once daily, Q3W.
Study NCT04997837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: CapeOx: 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~FOLFOX: 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off.
Study NCT04997837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: CapeOx: 130 mg/m2 (body surface area) solution intravenously once-daily, followed by 20 days off.~FOLFOX: 85 mg/m2 (body surface area) solution intravenously once-daily, followed by 13 days off.
Study NCT04997837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: CapeOx: 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
Study NCT04733144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 1,125 mg dexamethasone 4,5 mg dexamethasone
Study NCT06308965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vessel sparing technique
Description: Vessel sparing
Study NCT05055453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyPhonak Junior App
Description: The app is an accessory to the hearing aids which allows the user to make adjustments to their hearing aid in real-time. The hearing aid does not require the use of the app, but the objective of this study is to evaluate the effects of the user adjustments made via the app on the participant's speech intelligibility with the hearing aid.
Study NCT05055453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phonak Sky hearing aid
Description: A Behind-The-Ear hearing aid (BTE) fit to hearing impaired persons with mild to severe hearing loss.
Study NCT06086314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reactive exercise training with ''FitPodz Light Trainer'' device in addition to a neurorehabilitation program
Description: Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Reaching forward and touching the sensor when the red light sensor is on, and withdrawing his/her hand as soon as the sensor goes out.
Study NCT04997837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: CapeOx: 1000 mg2 (body surface area) bid orally in 14 days, followed by 7 days off.
Study NCT04997837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur-gimeracil-oteracil potassium
Description: SOX: 40 - 60 mg bid orally in 14 days, followed by 7 days off
Study NCT04890145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RW-Precision-Coupler
Description: Implantation of the RW-Precision-Coupler together with FMT-VORP 503
Study NCT05063916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: Given By IV
Study NCT04949399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Description: Injection
Study NCT06086314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reactive exercise training with co-contraction with ''FitPodz Light Trainer'' device in addition to a neurorehabilitation program.
Description: Attending the neurorehabilitation program that includes scapula mobilization, trunk elongation training in sitting, and training lumbar stabilizers with bridge activity. Reaching forward and touching the sensor when the green light sensor is on, and holding his/her hand on the sensor for 5 seconds and then withdrawing it.
Study NCT04997837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-gimeracil-oteracil potassium
Description: SOX: 40 - 60 mg bid orally in 14 days, followed by 7 days off
Study NCT04997837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: FOLFOX：2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W
Study NCT04997837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: FOLFOX：2400-2800mg/m2/d continuous intravenous pumping for 48h, Q2W
Study NCT04997837 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 1.8 Gy/Fx, 45-50.4 Gy
Study NCT06021665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fortetropin supplement
Description: Test Formulation: 10g serving Calories: 64.8g Carbohydrates: 0.45g Fats: 5.5g Protein: 3.38g
Study NCT06021665 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cheese protein
Description: The cheese powder will act as the control product. Cheese powder has been chosen as it matches the macronutrient content of the test product, but without the active ingredient.~Control Formulation: 20g serving Calories: 93g Carbohydrates: 8g Fats: 5g Protein: 3g
Study NCT05591989 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEUROMARK System
Description: The NEUROMARK System is indicated for use in otorhinolaryngology (ENT) surgery for creation of radiofrequency (RF) lesions to disrupt posterior nasal nerves in patients with chronic rhinitis.
Study NCT06308965 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vessel ligation technique
Description: Vessel ligation
Study NCT04234451 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SPA acupuncture
Description: For patients in the AA group, acupuncture was performed at a selected point in the SPG by inserting the needle from the lower border of the zygomatic arch, posterior to the suture protuberance between the zygomatic process and temporal process. The needle was directed obliquely anteriorly, until nearly the whole needle was beneath the skin, and then rotated until the patient felt de-qi sensations . The patients in the AA group received four courses of active acupuncture(visit 1,2,3 and 4), twice a week during weeks 1 and 2, and then followed-up for a further 2 weeks (visit 5 during week 3 and visit 6 during week 4).